Abstract:Platelet-type von Willebrand disease (vWD) and pseudo-vWD are two recently described intrinsic platelet defects characterized by enhanced ristocetin-induced agglutination in platelet-rich plasma. A similar finding is also typical of type IIB vWD, where it has been related to a von Willebrand factor (vWF) rather than a platelet abnormality. Platelet aggregation induced by unmodified human vWF in the absence of other stimuli has been reported in pseudo-vWD. In this study we demonstrate that vWF induces aggregation in platelet-type but not type IIB vWD. Aggregation is observed when normal plasma cryoprecipitate or purified vWF are added to platelet-rich plasma. Cryoprecipitate also aggregates washed platelets, although at higher concentrations than required for platelet-rich plasma. Purified vWF, however, induces significant aggregation of washed platelets only when plasma is added. EDTA inhibits vWF-induced aggregation. Its effect can be overcome by calcium but much less effectively by magnesium ions. Unstimulated platelets in platelet-rich plasma from patients with platelet-type but not type IIB vWD bind 125I-vWF in a specific and saturable manner. All different sized multimers of vWF become associated with platelets. Both aggregation and binding exhibit a similar vWF concentration dependence, suggesting that a correlation exists between these two events. Removal of ADP by appropriate consuming systems is without effect upon such binding or upon vWF-induced aggregation. Thrombin-induced 125I-vWF binding to washed platelets is normal in platelet-type as well as type IIB vWD. These results demonstrate that a specific binding site for unmodified human vWF is exposed on unstimulated platelets in platelet-type vWD. The relatively high vWF concentrations required for aggregation and binding may explain the lack of significant in vivo aggregation and thrombocytopenia in these patients. Moreover, these studies provide additional evidence that platelet-type and type IIB vWD are different diseases with distinct pathogeneses.

[Biology of von Willebrand factor and pathogenesis of von Willebrand disease]

von Willebrand disease

Platelet-Type von Willebrand Disease: New Insights into the Molecular Pathophysiology of a Unique Platelet Defect

Platelet-type von Willebrand's disease: characterization of a new bleeding disorder

Mechanisms of thrombocytopenia in platelet-type von Willebrand disease

Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease.

Von Willebrand factor deficiency and atherosclerosis

Diagnosis and treatment of von Willebrand disease in 2024 and beyond

von Willebrand disease: A guide for the internist

Dynamic and Functional Linkage Between Von Willebrand Factor and ADAMTS-13 with Aging: an Atherosclerosis Risk in Community Study.

Shear Stress-Induced Activation of von Willebrand Factor and Cardiovascular Pathology

Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what's new on the horizon?

Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects

A rare case of acquired von Willebrand syndrome type 2B: diagnosis, treatment, and underlying pathophysiology

Numerical study of ultra-large von Willebrand factor multimers in coagulopathy

von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.

Current and emerging therapies as potential treatment for people with von Willebrand disease

Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N

Frequency of Platelet type versus Type 2B von Willebrand Disease

Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder

A Compound Heterozygosis of Two Novel Mutations in vWF Exacerbates vWD in a Chinese Pedigree